14.2.2 Secondary endpoints

14.2.2.14-17 Evaluation of grading of bone marrow fibrosis and QOL

Table 14.2.2.16: Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), after 3 months of Ruxolitinib induction therapy, at transplantation (for SCT arm), 6 months, 1 year, 2 years and 3 years - Full Analysis Population

Treatment arm	Visit	MPN-SAF TSS	N (%)
ContRuxo	Before Ruxolitinib induction therapy	1	2 (14.3%)
		2	2 (14.3%)
		4	2 (14.3%)
		5	4 (28.6%)
		6	1 (7.1%)
		7	2 (14.3%)
		N.A.	1 (7.1%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Treatment arm	Visit	MPN-SAF TSS	N (%)
ContRuxo	After 3 months of Ruxolitinib induction therapy	0	1 (7.1%)
		1	4 (28.6%)
		3	2 (14.3%)
		4	2 (14.3%)
		5	2 (14.3%)
		6	1 (7.1%)
		7	1 (7.1%)
		Missing	1 (7.1%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Table 14.2.2.16: Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), after 3 months of Ruxolitinib induction therapy, at transplantation (for SCT arm), 6 months, 1 year, 2 years and 3 years - Full Analysis Population

Treatment arm	Visit	MPN-SAF TSS	N (%)
ContRuxo	After 6 months of Ruxolitinib continuous therapy	0	1 (7.1%)
		1	1 (7.1%)
		3	1 (7.1%)
		4	1 (7.1%)
		6	1 (7.1%)
		8	2 (14.3%)
		9	1 (7.1%)
		10	1 (7.1%)
		Missing	5 (35.7%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Table 14.2.2.16: Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), after 3 months of Ruxolitinib induction therapy, at transplantation (for SCT arm), 6 months, 1 year, 2 years and 3 years - Full Analysis Population

Treatment arm	Visit	MPN-SAF TSS	N (%)
ContRuxo	After 1 year of Ruxolitinib continuous therapy	1	2 (14.3%)
		2	2 (14.3%)
		3	1 (7.1%)
		7	1 (7.1%)
		Missing	8 (57.1%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Table 14.2.2.16: Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), after 3 months of Ruxolitinib induction therapy, at transplantation (for SCT arm), 6 months, 1 year, 2 years and 3 years - Full Analysis Population

Treatment arm	Visit	MPN-SAF TSS	N (%)
ContRuxo	After 2 years of Ruxolitinib continuous therapy	3	1 (7.1%)
		N.A.	1 (7.1%)
		Missing	12 (85.7%)
	After 3 years of Ruxolitinib continuous therapy	2	1 (7.1%)
		3	1 (7.1%)
		Missing	12 (85.7%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Table 14.2.2.16: Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), after 3 months of Ruxolitinib induction therapy, at transplantation (for SCT arm), 6 months, 1 year, 2 years and 3 years - Full Analysis Population

Treatment arm	Visit	MPN-SAF TSS	N (%)
SCT	Before Ruxolitinib induction therapy	0	3 (5.3%)
		1	5 (8.8%)
		2	11 (19.3%)
		3	8 (14.0%)
		4	10 (17.5%)
		5	10 (17.5%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Table 14.2.2.16: Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), after 3 months of Ruxolitinib induction therapy, at transplantation (for SCT arm), 6 months, 1 year, 2 years and 3 years - Full Analysis Population

Treatment arm	Visit	MPN-SAF TSS	N (%)
SCT	Before Ruxolitinib induction therapy	6	5 (8.8%)
		7	1 (1.8%)
		8	1 (1.8%)
		N.A.	1 (1.8%)
		Missing	2 (3.5%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Table 14.2.2.16: Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), after 3 months of Ruxolitinib induction therapy, at transplantation (for SCT arm), 6 months, 1 year, 2 years and 3 years - Full Analysis Population

Treatment arm	Visit	MPN-SAF TSS	N (%)
SCT	After 3 months of Ruxolitinib induction therapy	0	1 (1.8%)
		1	8 (14.0%)
		2	11 (19.3%)
		3	8 (14.0%)
		4	7 (12.3%)
		5	4 (7.0%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Table 14.2.2.16: Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), after 3 months of Ruxolitinib induction therapy, at transplantation (for SCT arm), 6 months, 1 year, 2 years and 3 years - Full Analysis Population

Treatment arm	Visit	MPN-SAF TSS	N (%)
SCT	After 3 months of Ruxolitinib induction therapy	6	3 (5.3%)
		7	2 (3.5%)
		8	1 (1.8%)
		9	1 (1.8%)
		Missing	11 (19.3%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Table 14.2.2.16: Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), after 3 months of Ruxolitinib induction therapy, at transplantation (for SCT arm), 6 months, 1 year, 2 years and 3 years - Full Analysis Population

Treatment arm	Visit	MPN-SAF TSS	N (%)
SCT	Allogeneic SCT day + 6 months	0	3 (5.3%)
		1	8 (14.0%)
		2	9 (15.8%)
		3	7 (12.3%)
		4	6 (10.5%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Table 14.2.2.16: Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), after 3 months of Ruxolitinib induction therapy, at transplantation (for SCT arm), 6 months, 1 year, 2 years and 3 years - Full Analysis Population

Treatment arm	Visit	MPN-SAF TSS	N (%)
SCT	Allogeneic SCT day + 6 months	5	1 (1.8%)
		6	3 (5.3%)
		7	1 (1.8%)
		9	1 (1.8%)
		Missing	18 (31.6%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Treatment arm	Visit	MPN-SAF TSS	N (%)
SCT	Allogeneic SCT day + 1 year	0	7 (12.3%)
		1	9 (15.8%)
		2	6 (10.5%)
		3	6 (10.5%)
		4	4 (7.0%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Treatment arm	Visit	MPN-SAF TSS	N (%)
SCT	Allogeneic SCT day + 1 year	5	1 (1.8%)
		6	1 (1.8%)
		8	2 (3.5%)
		9	1 (1.8%)
		Missing	20 (35.1%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Treatment arm	Visit	MPN-SAF TSS	N (%)
SCT	Allogeneic SCT day + 2 years	0	8 (14.0%)
		1	8 (14.0%)
		2	4 (7.0%)
		3	4 (7.0%)
		4	2 (3.5%)
		Missing	31 (54.4%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Page 14 of 15

Treatment arm	Visit	MPN-SAF TSS	N (%)
SCT	Allogeneic SCT day + 3 years	0	6 (10.5%)
		1	11 (19.3%)
		2	2 (3.5%)
		3	2 (3.5%)
		Missing	36 (63.2%)

ContRuxo: Ruxolitinib continuous therapy. MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
QOL:Quality of Life. SCT: Allogeneic stem cell transplantation. All percentage values are rounded to 1 decimal place.
Total N for Full Analysis Population allocated to SCT arm = 57 and ContRuxo arm=14.
QOL:MPN-SAF TSS values at SCT not shown since QOL measurements not taken at SCT.

Page 15 of 15